The National Health Council (NHC) submits this letter on the Centers for Medicare & Medicaid Services’ (CMS’) Guidance entitled “State Relief and Empowerment Waivers” and requests its withdrawal. The NHC […]
Letters + Comments
Patient-Focused Drug Development Guidance: Methods To Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments
The National Health Council (NHC) is pleased to provide comments on the Food and Drug Administration’s (FDA) discussion documents related to Guidance 2: “Methods to Identify What is Important to […]
CMS’s Accountable Care Organizations Pathways to Success
The National Health Council (NHC) appreciates the opportunity to respond to the Proposed Rule entitled, “Medicare Shared Savings Program; Accountable Care Organizations Pathways to Success” (the Proposed Rule). The NHC […]
FDA Standard Core Clinical Outcome Assessments and Endpoints
The NHC supports the FDA’s interest in promoting the “development of publicly available, standard core sets of Clinical Outcome Assessment (COA) measures for specific disease indications.” We appreciate the amount […]
Letter to Secretary Azar on the Administration’s Step Therapy Policy
In a letter to the Secretary of the Department of Health and Human Services Alex Azar, we strongly urge the Administration to accompany the policy allowing Medicare Advantage (MA) plans […]
Proposed Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs
The NHC fully supports the Administration’s efforts to increase transparency of hospital charges and to combat the nation’s opioid crisis through increasing access to alternative pain management techniques. However, we […]
FDA’s Draft Guidance on Patient-Focused Drug Development: Collecting Comprehensive and Representative Input
The National Health Council (NHC) appreciates the opportunity to provide comments on the Food and Drug Administration’s (FDA’s) draft guidance on Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. The […]
Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
The NHC appreciates the Administration’s goals to improve competition, promote better negotiation, lower list prices, and reduce out-of-pocket costs. We are committed to working with Congress and the Administration on […]
Proposed Rule: Short-Term, Limited-Duration Insurance (STLD) Insurance Plans
The Proposed Rule’s expansion of short-term, limited-duration (STLD) insurance plans from three months to 364 days and allowing them to become renewable will have a severe negative impact on the […]
Letter to Congress Expressing Concern with Short-Term Limited Duration Plans
The National Health Council (NHC) submits this letter, with 112 other patient advocacy organizations, to Congressional leadership expressing concern with Short-Term Limited Duration Plans. “Our 113 organizations represent millions of […]